Cellectis (NASDAQ:CLLS) Now Covered by StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS) in a research note issued on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Barclays lowered their target price on Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th.

Cellectis Trading Down 1.4 %

Shares of Cellectis stock opened at $2.10 on Wednesday. The stock has a market capitalization of $116.73 million, a P/E ratio of -1.62 and a beta of 3.08. Cellectis has a 12-month low of $1.41 and a 12-month high of $3.38. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. The company has a 50-day simple moving average of $1.84 and a 200 day simple moving average of $2.01.

Cellectis (NASDAQ:CLLS) last posted its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). The firm had revenue of $18.05 million during the quarter, compared to the consensus estimate of $5.00 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. During the same quarter last year, the firm posted ($0.31) EPS. Research analysts expect that Cellectis will post -0.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Principal Financial Group Inc. lifted its stake in shares of Cellectis by 2.9% during the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after acquiring an additional 12,467 shares during the period. XTX Topco Ltd bought a new stake in Cellectis during the 2nd quarter worth about $29,000. First Affirmative Financial Network acquired a new position in Cellectis during the 3rd quarter valued at about $45,000. Finally, Long Focus Capital Management LLC boosted its stake in shares of Cellectis by 2.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after purchasing an additional 130,000 shares during the last quarter. 63.90% of the stock is currently owned by institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.